Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Gestational diabetes practice guidelines.

BIBLIOGRAPHIC SOURCE(S)

  • International Diabetes Center. Gestational diabetes practice guidelines. Minneapolis (MN): International Diabetes Center; 2003. 2 p.

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Staged diabetes management: a systematic approach. Minneapolis (MN): Matrex, International Diabetes Center; 2000. Gestational diabetes practice guidelines. p. 173-205.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

The following is an outline of practice guidelines for management of gestational diabetes mellitus. A detailed management plan and accompanying DecisionPaths can be found in the original guidelines:

Screening

Screen between the 24th and 28th gestational weeks; with any risk factor, consider screening at first prenatal visit.

Screen with 50-gram glucose challenge test: 1-hour plasma glucose >140 mg/dL positive; >120 mg/dL suspected.

Risk Factors

  • Body mass index >25 kg/m2 (especially waist-to-hip ratio >1)
  • Family history of type 2 diabetes (especially first-degree relatives)
  • Age older than 25 years
  • Multiparity
  • Previous gestational diabetes: Macrosomic or large-for-gestational age infant (e.g., >9 lbs. or 4000 grams)
  • Previous impaired fasting glucose with fasting plasma glucose 110 to 125 mg/dL
  • Previous impaired glucose tolerance with oral glucose tolerance test 2-hour glucose value 140 to 199 mg/dL
  • American Indian or Alaska Native, African American, Asian, Hispanic, Pacific Islander

Diagnosis

Plasma Glucose

100 gram oral glucose tolerance test after 8 to 10 hours overnight fast:

Fasting >95 mg/dL, 1 hour >180 mg/dL, 2 hour >155 mg/dL, 3 hour >140 mg/dL; two abnormal values required for diagnosis; if one abnormal, consider self-monitored blood glucose for 7 days; if average fasting blood glucose >95 mg/dL or average 2-hour post-meal >120 mg/dL, re-evaluate for gestational diabetes mellitus. See "Gestational: Master DecisionPath" in the full-text guideline.

Symptoms

Usually none. Rarely, increased urination, thirst, and appetite; nocturia; weight loss

Urine Ketones

Usually negative; positive can indicate starvation ketosis

Treatment Options

Medical nutrition therapy; Glyburide Stage; insulin Stages 3, 4

Targets

Self-Monitored Blood Glucose

  • All values within target range
  • Pre-meal and bedtime: 60 to 95 mg/dL
  • Post-meal: <120 mg/dL 2 hours after start of meal; <140 mg/dL 1 hour after start of meal

Hemoglobin A1c(HbA1c)

May be used to evaluate prior hyperglycemia, but is not used in gestational diabetes management; should be within normal range

Urine Ketones (Fasting)

Negative

Monitoring

Self-Monitored Blood Glucose

6 to 7 times/day; before and 1 to 2 hours after start of meals, and at bedtime; 4 times/day minimum; fasting and 1 to 2 hours after start of meals

Method

Meter with memory and log book

Urine Ketones (Fasting)

Every morning until negative for 7 days, then every other morning

Follow-Up

Pre-natal

Phone 1 to 2 times a week to review self-monitored blood glucose data; office visit every 2 weeks up to 36 weeks, then weekly; self-monitored blood glucose data (download and check meter); frequency of hypoglycemia; weight or body mass index; medications; blood pressure; medical nutrition therapy; exercise

Fetal Monitoring

Kick counts at 28 weeks; non-stress test at 34 weeks and until end of pregnancy

After Delivery

In hospital: Check fasting blood glucose and 2 hours after breakfast each day.

After discharge: Check fasting blood glucose and blood glucose 2 hours after breakfast 1 day/week until first postpartum visit. If fasting blood glucose >120 mg/dL, and/or post-prandial blood glucose >160 mg/dL, evaluate for diabetes immediately.

6 weeks: Nutrition education if needed

3 to 6 months: Evaluate for diabetes and yearly thereafter

CLINICAL ALGORITHM(S)

Algorithms are provided for management of gestational diabetes in the form of a Master DecisionPath as well as separate detailed DecisionPaths for:

  • Screening and Diagnosis of Gestational Diabetes
  • Gestational Diabetes Education
  • Gestational Diabetes Education Topics
  • Gestational Diabetes Medical Nutrition Therapy/Start
  • Gestational Diabetes Medical Nutrition Therapy/Adjust
  • Gestational Diabetes Insulin Stage 2
  • Gestational Diabetes Insulin Stage 3A/Start
  • Self-Monitoring of Blood Glucose Adherence for Gestational Diabetes
  • Psychological and Social Assessment

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is not specifically stated for each recommendation. However, throughout the guideline document, the evidence used as the basis for the recommendations is discussed.

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • International Diabetes Center. Gestational diabetes practice guidelines. Minneapolis (MN): International Diabetes Center; 2003. 2 p.

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2000 (revised 2003)

GUIDELINE DEVELOPER(S)

International Diabetes Center - Private Nonprofit Organization

GUIDELINE DEVELOPER COMMENT

The International Diabetes Center is part of the Institute for Research and Education HealthSystem Minnesota. HealthSystem Minnesota, an integrated care system, also includes Methodist Hospital, Park Nicollet Clinic, and The Foundation.

The International Diabetes Center is a World Health Organization (WHO) Collaborating Center for Diabetes Education, Translation and Computer Technology.

SOURCE(S) OF FUNDING

This publication is supported by an unrestricted educational grant from Becton Dickinson and Company.

GUIDELINE COMMITTEE

Not stated

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Authors: Roger S. Mazze, PhD, Ellie S. Strock, RN, ANP, CDE; Gregg D. Simonson, PhD, Richard M. Bergenstal, MD, Donnell D. Etzwiler, MD

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Staged diabetes management: a systematic approach. Minneapolis (MN): Matrex, International Diabetes Center; 2000. Gestational diabetes practice guidelines. p. 173-205.

GUIDELINE AVAILABILITY

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

None available

NGC STATUS

This summary was completed by ECRI on May 21, 2001. This summary was updated by ECRI on February 18, 2004. The information was verified by the guideline developer on March 11, 2004.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

Copyright 2000. International Diabetes Center, Institute for Research and Education. All rights reserved. No part of these Guidelines may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, photocopying, recording or otherwise, without prior written permissions of the International Diabetes Center. These Guidelines should not be interpreted as including all available and proper methods of diabetes care. The decision regarding any specific treatment modality must be made by the health care professional with consideration of the particular circumstances presented by the patient and the needs and resources particular to the community or institution.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo